1. Reduced firing rates of pyramidal cells in the frontal cortex of APP/PS1 can be restored by acute treatment with levetiracetam.
- Author
-
Klee JL, Kiliaan AJ, Lipponen A, and Battaglia FP
- Subjects
- Amyloid beta-Protein Precursor genetics, Animals, Disease Models, Animal, Levetiracetam therapeutic use, Male, Mice, Transgenic, Presenilin-1 genetics, Action Potentials drug effects, Alzheimer Disease drug therapy, Alzheimer Disease physiopathology, Amyloidosis drug therapy, Amyloidosis physiopathology, Frontal Lobe cytology, Levetiracetam pharmacology, Pyramidal Cells physiology
- Abstract
In recent years, aberrant neural oscillations in various cortical areas have emerged as a common physiological hallmark across mouse models of amyloid pathology and patients with Alzheimer's disease. However, much less is known about the underlying effect of amyloid pathology on single cell activity. Here, we used high-density silicon probe recordings from frontal cortex area of 9-month-old APP/PS1 mice to show that local field potential power in the theta and beta band is increased in transgenic animals, whereas single-cell firing rates, specifically of putative pyramidal cells, are significantly reduced. At the same time, these sparsely firing pyramidal cells phase-lock their spiking activity more strongly to the ongoing theta and beta rhythms. Furthermore, we demonstrated that the antiepileptic drug, levetiracetam, counteracts these effects by increasing pyramidal cell firing rates in APP/PS1 mice and uncoupling pyramidal cells and interneurons. Overall, our results highlight reduced firing rates of cortical pyramidal cells as a pathophysiological phenotype in APP/PS1 mice and indicate a potentially beneficial effect of acute levetiracetam treatment., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF